title: [An update on the treatment options for multiple sclerosis].
abstract: The treatment of multiple sclerosis (MS) has been remarkably progressed, especially in disease modifying therapies (DMTs). Recently, fingolimod, a novel oral DMT, was added to treatment options for relapsing-remitting MS (RRMS) in Japan. In Western countries, more kinds of DMTs are available for treatment for RRMS. Further, clinical trials on many drugs including DMTs are on-going, and the arrival of multiple options for MS is promising. This article reviews the recent progress in current therapeutic strategies for MS and the potential options for future MS treatments.
authors.affiliation: Department of Clinical Research, Hokkaido Medical Center, Sapporo, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Niino
mesh_terms: D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use; D007564:Japan; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D007372:Interferons; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine